Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC decreased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 16.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 243,005 shares of the specialty pharmaceutical company’s stock after selling 48,679 shares during the period. Wedge Capital Management L L P NC owned 0.40% of Jazz Pharmaceuticals worth $29,926,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. grew its position in Jazz Pharmaceuticals by 19.3% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 7,846 shares of the specialty pharmaceutical company’s stock worth $837,000 after purchasing an additional 1,272 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 1.0% during the second quarter. Envestnet Asset Management Inc. now owns 64,096 shares of the specialty pharmaceutical company’s stock worth $6,841,000 after buying an additional 619 shares during the period. Dimensional Fund Advisors LP grew its holdings in Jazz Pharmaceuticals by 48.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company’s stock worth $130,447,000 after buying an additional 398,549 shares in the last quarter. Amalgamated Bank increased its position in Jazz Pharmaceuticals by 4.7% in the 2nd quarter. Amalgamated Bank now owns 39,125 shares of the specialty pharmaceutical company’s stock valued at $4,176,000 after acquiring an additional 1,745 shares during the period. Finally, Mercer Global Advisors Inc. ADV raised its stake in Jazz Pharmaceuticals by 51.7% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 3,485 shares of the specialty pharmaceutical company’s stock valued at $372,000 after acquiring an additional 1,187 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. TD Cowen decreased their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Robert W. Baird boosted their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $177.00.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $121.18 on Friday. The company has a market cap of $7.33 billion, a price-to-earnings ratio of 17.07, a PEG ratio of 0.88 and a beta of 0.56. The business has a 50 day moving average price of $122.78 and a 200 day moving average price of $114.60. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,253 shares of company stock valued at $1,001,434 over the last three months. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.